biostudies-literatureJia CHebei Province Medical Science Research Project Plan12765https://www.ebi.ac.uk/biostudies/studies/S-EPMC11997058biostudies-literatureUnknown15(1)Hormone receptor HR-positive/HER2-negative (HR+/HER2-) breast cancer is the most common subtype in China, representing 60-70% of cases, with a rising incidence due to aging demographics and lifestyle changes. CDK4/6 inhibitors such as palbociclib, ribociclib and abemaciclib have been proven effective in treating HR+/HER2 - advanced or metastatic breast cancer (ABC/MBC), though they may increase healthcare costs. This study aims to compare the efficacy, safety and cost-effectiveness of CDK4/6 inhibitors for the second-line treatment of HR+/HER2 - ABC/MBC from the Chinese healthcare perspective. A cohort-based partitioned survival model was utilized, drawing on the survival data published from PALOMA-3, MONALEESA-3 and MONARCH-2 trials. Costs, and quality-adjusted life years (QALYs) were useScientific reportsCost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2- advanced or metastatic breast cancer in China.PMC1199705820240243Wang MLi SJia CShi FZhang SFeng BXu HWang JfalseCost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2- advanced or metastatic breast cancer in China.Hormone receptor HR-positive/HER2-negative (HR+/HER2-) breast cancer is the most common subtype in China, representing 60-70% of cases, with a rising incidence due to aging demographics and lifestyle changes. CDK4/6 inhibitors such as palbociclib, ribociclib and abemaciclib have been proven effective in treating HR+/HER2 - advanced or metastatic breast cancer (ABC/MBC), though they may increase healthcare costs. This study aims to compare the efficacy, safety and cost-effectiveness of CDK4/6 inhibitors for the second-line treatment of HR+/HER2 - ABC/MBC from the Chinese healthcare perspective. A cohort-based partitioned survival model was utilized, drawing on the survival data published from PALOMA-3, MONALEESA-3 and MONARCH-2 trials. Costs, and quality-adjusted life years (QALYs) were use2025-01-01T00:00:00Z2025 Apr2025-07-03T03:06:59.947Z2025-07-03T03:06:59.947ZS-EPMC119970584022934610.1038/s41598-025-97504-3